Tidomet/Tidomet CR Dosage/Direction for Use

Tidomet 100 mg/25 mg: A suggested initial dose for patients not previously treated with levodopa is 1 tablet three times daily, increased gradually, in increments of carbidopa 12.5 mg with levodopa 50 mg or carbidopa 25 mg with levodpa 100 mg everyday or on alternate days, as necessary. The usual maintenance dosage range is carbidopa 75 to 200 mg with levodopa 750 mg to 2 g daily in divided doses. Carbidopa doses greater than 200 mg daily are not generally exceeded.
The initial dose of co-careldopa in patients previously treated with levodopa should be about ¹/₄ of the dose previously being taken, thus patients taking less than 1.5 g of levodopa daily a suggested initial dose is 1 tablet three or four times daily; a suggested initial dose for patients taking more than 1.5 g of levodopa daily is 1 tablet three to four times daily.
Tidomet 250 mg/25 mg: Carefully titrate dosage in each patient. Initiate treatment with 1 tablet of co-careldopa. Plus 3 times a day. Dosage may be increased by 1 tablet a day or every other day as necessary until a dosage of 8 tablets of co-careldopa. Plus per day is reached. If co-careldopa LS is used, initiate 1 tablet 3 or 4 times a day and increased by 1 tablet every day or every other day until a total 8 tablets i.e. 2 tablets 4 times a day is reached. Transferring patients from levodopa to co-careldopa, levodopa must be discontinued at least before 8 hours. ¹/₄th of the previous levodopa dosage may be started as co-careldopa. Patients taking less than 1500 mg of levodopa per day should be started on one tablet of co-careldopa. Plus 3-4 times a day. Maintenance therapy should be individualized and adjusted according to the desired therapeutic response. When a greater proportion of carbidopa is required, one tablet of co-careldopa. Plus may be substituted for each tablet of co-careldopa LS. When more levodopa is required co-cereldopa forte should be substituted at a dosage of 1 tablet 3 or 4 times a day. If necessary the dosage may be increased by ¹/₂ or 1 tablet everyday or every other day to a maximum of 8 tablets a day. The occurrence of involuntary movements may require dosage reduction; Blepharospasm may be a useful early sign of excess dosage in some patients.
Tidomet CR: Patients already receiving levodopa therapy and for those currently receiving levodopa alone: Initial dose is 1 tablet twice daily adjusted according to response at intervals of not less than 3 days. It is recommended that for patients whose are not already receiving initial dosages should not exceed 600 mg of levodopa. Or as prescribed by the physician.
Patients already receiving a conventional preparation: Initial dose similar to that of the conventional preparation but the dosing intervals should be prolonged and are normally between 4 to 12 hours. The initial substitution of the controlled release preparation should provide not more than 10% more levodopa than was previously given for doses greater than 900 mg daily. Doses and intervals may then be altered according to clinical response, allowing at least 3 days between adjustments. Up to 30% more levodopa may be required in the controlled release preparation than was previously administered in the conventional preparation. Or as prescribed by the physician.
Average maintenance dose of controlled release preparation lies between the range of Carbidopa 100 mg with Levodopa 400 mg to Carbidopa 400 mg with Levodopa 1.6 g.